Ignite Creation Date:
2025-12-25 @ 4:08 AM
Ignite Modification Date:
2026-02-25 @ 7:08 PM
Study NCT ID:
NCT02282020
Status:
COMPLETED
Last Update Posted:
2022-07-26
First Post:
2014-10-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-02-06
Start Date Type:
ACTUAL
Primary Completion Date:
2018-10-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-07-19
Completion Date Type:
ACTUAL
First Submit Date:
2014-10-20
First Submit QC Date:
None
Study First Post Date:
2014-11-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-10-03
Results First Submit QC Date:
None
Results First Post Date:
2019-12-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-07-25
Last Update Post Date:
2022-07-26
Last Update Post Date Type:
ACTUAL